StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
RBC Capital Downgrades BioMarin Pharmaceutical Inc. (BMRN) to Sector Perform, After FDA CRL
August 19, 2020 11:12 AM
RBC Capital analyst Kennen MacKay downgraded BioMarin Pharmaceutical Inc. (NASDAQ ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Downgrades
Next Articles
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $120 at Baird; Sees at Least a 2-Year Valrox Delay Following CRL
August 19, 2020 11:30 AM